Dr. Yogev is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2300 Childrens Plaza
Chicago, IL 60614Phone+1 773-880-4757Fax+1 773-880-3208
Education & Training
- McGaw Medical Center of Northwestern UniversityResidency, Pediatrics, 1975 - 1976
- The Hebrew University of Jerusalem Hadassah Medical SchoolClass of 1969
Certifications & Licensure
- IL State Medical License 1977 - 2026
- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Fellow (FAAP) American Academy of Pediatrics
Clinical Trials
- A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection
- A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children
- The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children
- Join now to see all
Publications & Presentations
PubMed
- 219 citationsThree-Year Multicenter Surveillance of Pneumococcal Meningitis in Children: Clinical Characteristics, and Outcome Related to Penicillin Susceptibility and Dexamethason...Moshe Arditi, Edward O. Mason, John S. Bradley, Tina Q. Tan, William J. Barson
Pediatrics. 1998-11-01 - 4 citationsConfounding by indication limits conclusions of study of palivizumab effectivenessThomas G. Boyce, Ram Yogev, John P. DeVincenzo, Leonard R. Krilov
Pediatrics. 2017-03-01 - 11 citationsPopulation Pharmacokinetics of Intramuscular and Intravenous Ketamine in Children.Christoph P. Hornik, Daniel Gonzalez, John N. van den Anker, Andrew M. Atz, Ram Yogev
Journal of Clinical Pharmacology. 2018-08-01
Press Mentions
- Effectiveness of Efavirenz-Based Antiretroviral Therapy for HIV-Infected ChildrenNovember 3rd, 2015
- Treating Opportunistic Infections Among HIV-Exposed and Infected Children: Recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of AmericaFebruary 1st, 2005
Grant Support
- Units For HIV/AIDS Clinical Trials NetworksNational Institute Of Allergy And Infectious Diseases2007–2012
- Pactg P1038: High Dose Lopinavir/Ritonavir With Or Without Saquinavir In HIV PTSNational Center For Research Resources2006–2007
- Pactg P1021: Emtricitabine In Combination With Efavirenz &Didanosine In ARTNational Center For Research Resources2006–2007
- Pactg 1020-A: Protease Inhibitor (Bms 232632) In Combination Regimen In ARTNational Center For Research Resources2006–2007
- Pediatric AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1993–2006
- Pharmacokinetics Of Antiretrovirals Following Gastrostomy Tube AdministrationNational Center For Research Resources2004
- Pactg P1030: A Phase I/II Study Of Lopinavir/Ritonavir In HIV-1 Infected InfantsNational Center For Research Resources2004
- Actg226--Oral Ganciclovir In HIV Infected Children With Asymptomatic CMVNational Center For Research Resources1998–1999
- Actg--Pharmacokinetic And Tolerance Study Of Oral GanciclovirNational Center For Research Resources1997
- Actg--Atovaquone /Azithromycin Compared To Trimethoprim-SulfamethoxazoleNational Center For Research Resources1997
- Phase I Safety And Tolerance Study Of M-AtovaquoneNational Center For Research Resources1996
- Pharmacokinetic And Tolerance Study Of Oral GanciclovirNational Center For Research Resources1996
- Pediatric AIDS Clinical Trials GroupNational Institute Of Allergy And Infectious Diseases1988–1992
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: